Schematic representation of double-stranded DNA. DNase I can generate single-chain nicks in both DNA strands at the indicated phosphate-oxygen bonds. The obtained oligonucleotides, which are at least two nucleotides long, bear a 5'-phosphate and a 3'-hydroxyl termini.
pancreas. This drastically intensified the biochemical investigations on and with DNase I. In 1950, Armstrong, et al., reported that partially purified bovine pancreatic DNase I reduced the viscosity of purulent cystic fibrosis (CF) lung secretions . Clinical trials with inhaled bovine DNase I followed soon after and showed clinical improvements in CF patients and patients with purulent secretions [9-11]. In 1958, bovine pancreatic DNase I (Dornavac) was approved in the United States as a mucolytic agent for human use . However, in the early 1960s, severe adverse reactions like bronchospasms and asthmatic attacks led to the withdrawal of bovine pancreatic DNase I from the market [13,14]. During the following decades, clinical interest in DNase I diminished, but DNase I received much attention once again when Shak, et al.  cloned the human version of it in 1990. In 1993, this led to the marketing of recombinant human (rh) DNase I under the trade name Pulmozyme® (Genentech Inc., San Francisco, CA) for use in CF patients. In this chapter, we will focus on the biochemical properties, clinical use, pharmacological aspects, and production of rhDNase I.
Was this article helpful?
Do You Suffer From ASTHMA Chronic asthma is a paralyzing, suffocating and socially isolating condition that can cause anxiety that can trigger even more attacks. Before you know it you are caught in a vicious cycle Put an end to the dependence on inhalers, buying expensive prescription drugs and avoidance of allergenic situations and animals. Get control of your life again and Deal With Asthma Naturally